

# Surgery to remove orbital bloody tumors through the conjunctiva by aid of a device that facilitates the procedure

<b>Submission date</b> 16/04/2020	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 24/04/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 03/06/2020	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Hemangioma is a benign tumor that is found to grow within the orbit. Most commonly located behind the eye globe, it can push the eye forward causing eye-bulging doctors call proptosis.

The tumor can be removed through surgery entering via the lower eyelid (transconjunctival orbitotomy) using cryotherapy. Cryotherapy uses imaging guidance, a needle-like applicator called a cryoprobe, and liquid nitrogen or argon gas to create intense cold to freeze and destroy diseased tissue, including cancer cells.

The aim of this study is to evaluate the safety and efficacy of cryo-assisted transconjunctival orbitotomy for the extraction of intraconal cavernous hemangiomas.

### Who can participate?

Patients with intraconal cavernous hemangiomas

### What does the study involve?

The transconjunctival approach will be used for cryo-assisted lesion extraction. Cases will be followed for six months after the surgery.

### What are the possible benefits and risks of participating?

Benefits: excision of the orbital tumors, avoid compression of the optic nerve and avoid exposure keratitis

Risks: trauma to the optic nerve, trauma to the globe, rupture of the mass and inability to remove the tumor

### Where is the study run from?

Mansoura ophthalmic center (Egypt)

### When is the study starting and how long is it expected to run for?

April 2017 to September 2018

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
Dr Abd El Ghafar, aiman\_eg\_123@yahoo.com

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Ayman Abd El Ghafar

**ORCID ID**  
<http://orcid.org/0000-0002-5127-7558>

**Contact details**  
Ophthalmology Center  
12 Gehan street  
Mansoura  
Egypt  
35516  
+20 (0)1005876138  
[ayman\\_gh@mans.edu.eg](mailto:ayman_gh@mans.edu.eg)

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
Nil known

## Study information

**Scientific Title**  
Transconjunctival cryo-assisted extraction of intraconal cavernous hemangioma

**Study objectives**  
is the transconjunctival cryo-assisted approach for excision of intraconal cavernous hemangioma is safe and effective?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 10/05/2017, Mansoura institutional review board (IRB) (Mansoura University Faculty of Medicine, Mansoura, Egypt; +20 (0)1092127930; IRB.MFM@hotmail.com), ref: R/17.05.26

**Study design**

Interventional non comparative single center case series

**Primary study design**

Interventional

**Secondary study design**

Non randomised study

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet.

**Health condition(s) or problem(s) studied**

Orbital intraconal cavernous hemangioma

**Interventions**

Excision of intraconal cavernous hemangiomas were performed through the transconjunctival approach assisted by the cryo-probe.

Patients enrolled were informed about the nature of surgery and benefits and possible complications of the procedure. they were admitted from May 2017 to August 2018 and followed for 6 months after surgery.

**Intervention Type**

Procedure/Surgery

**Primary outcome measure**

The success of the operation and complications measured using direct interview of patients after six months

**Secondary outcome measures**

None

**Overall study start date**

02/04/2017

**Completion date**

14/09/2018

## Eligibility

### Key inclusion criteria

Patients with intraconal cavernous hemangiomas

### Participant type(s)

Patient

### Age group

Adult

### Sex

Both

### Target number of participants

18

### Key exclusion criteria

Intraconal, non-compressible, solid lesions that simulate cavernous hemangioma e.g. schwannoma, solitary neurofibroma, and fibrous histiocytoma

### Date of first enrolment

14/05/2017

### Date of final enrolment

14/08/2018

## Locations

### Countries of recruitment

Egypt

### Study participating centre

Mansoura ophthalmic center

Gomhoria steet

Mansoura

Egypt

35516

## Sponsor information

### Organisation

Mansoura University

**Sponsor details**

Mansoura Ophthalmic Center  
Mansoura Faculty of Medicine  
Elgomhoria street  
Mansoura  
Egypt  
35516  
+20 (0)1000641607  
aiman\_eg\_123@yahoo.com

**Sponsor type**

Hospital/treatment centre

**Website**

<http://ophc.mans.edu.eg/>

**ROR**

<https://ror.org/01k8vtd75>

**Funder(s)****Funder type**

Not defined

**Funder Name**

Investigator initiated and funded

**Results and Publications****Publication and dissemination plan**

BMC ophthalmology journal.

**Intention to publish date**

15/05/2020

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**IPD sharing plan summary**

Available on request